^
Association details:
| Biomarker: | EGFR wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features
Published date:
04/05/2022
Excerpt:
The objective of the study was to study the potency of PD-1 inhibitors in patients with NSCLC....Combined results showed that PD-1 inhibitors provided longer OS for EGFR wild-type individuals (HR 0.68; 95% CI, 0.60–0.78; P <0.00001), while did not for EGFR mutant individuals (HR 1.04; 95% CI, 0.70–1.53; P = 0.85) compared with non-PD-1 inhibitor therapy (Figure 3G).
DOI:
10.3389/fimmu.2022.875093
